AbbVie

Yahoo Finance • 21 hours ago

Why Analysts See AbbVie’s Story Shifting After Strategic Wins and Growth Upgrades

AbbVie shares have seen their consensus analyst price target rise from $227.22 to $232.78 per share, reflecting growing optimism from Wall Street. This shift follows positive business developments, including key litigation wins, robust sal... Full story

Yahoo Finance • 2 days ago

Catalyst Watch: China drama, big banks report, Oracle and Nvidia events, end-of-life day for Windows 10

[Wall Street Aerial] Art Wager/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY... Full story

Yahoo Finance • 2 days ago

Global Protein Drugs Market to Reach $655.7 Billion by 2029

BCC Research LLC “BCC Research analyzes how innovation in biomanufacturing, ESG trends, and strategic investments are shaping the next frontier of protein-based therapeutics.” Boston, Oct. 10, 2025 (GLOBE NEWSWIRE) -- As demand for targe... Full story

Yahoo Finance • 2 days ago

Align Tech cut to Hold at Jefferies after clear aligner survey

[Wall Street-Street Sign] P_Wei/E+ via Getty Images Shares of Align Technology (NASDAQ:ALGN [https://seekingalpha.com/symbol/ALGN]) fell ~5% on Friday after Jefferies downgraded the dental product manufacturer to Hold from Buy, citing res... Full story

Yahoo Finance • 2 days ago

Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly

By Bhanvi Satija and Maggie Fick LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to lower... Full story

Yahoo Finance • 3 days ago

SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer

By the makers of BOTOX® Cosmetic (onabotulinumtoxinA), SkinMedica®'s new packaging features a refreshed logo, modernized look, and luxe copper color palette. The brand's new HA5® moisturizer is designed to support the skin barrier and mic... Full story

Yahoo Finance • 3 days ago

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

ROCKVILLE, Md., Oct. 9, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present interim data from the Phase II ALTITUDE® trial evaluating suprachoroidal delivery of surabgene lomparvovec (ABBV-RGX-314, sura-... Full story

Yahoo Finance • 3 days ago

Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab

Company Logo The bispecific antibodies market presents key opportunities in oncology, autoimmune, and infectious diseases, driven by rapid technological advancements and strategic collaborations. Regional manufacturing and diverse supplie... Full story

Yahoo Finance • 4 days ago

Cramer’s ‘Absolute Favorite’ AbbVie Rises After Study Completions and Upgrade

AbbVie Inc. (NYSE:ABBV) is one of Jim Cramer’s Recession-Proof Stock Picks. Cramer calls the stock his ‘absolute favorite,’ and it is followed by updates on the completion of two key studies.Cramer’s ‘Absolute Favorite’ AbbVie Rises After... Full story

Yahoo Finance • 4 days ago

AbbVie Inc. (ABBV) Starts Building $70 Million Expansion of Its AbbVie Bioresearch Centre in Worcester, Massachusetts

With significant hedge fund interest and trending on Reddit, AbbVie Inc. (NYSE:ABBV) secures a spot on our list of the 10 Best Non-Tech Stocks to Buy According to Reddit.AbbVie Inc. (ABBV) Starts Building $70 Million Expansion of Its AbbVi... Full story

Yahoo Finance • 5 days ago

Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes

AUSTIN, Texas and TOKYO, Oct. 7, 2025 /PRNewswire/ -- The Neuromuscular Disease Therapeutics Market is entering a period of accelerated growth, supported by breakthroughs in gene therapy, antisense oligonucleotides (ASOs), monoclonal antib... Full story

Yahoo Finance • 6 days ago

AbbVie succeeds in mid-stage study of neurological disease treatment

[Neuron system disease] AbbVie (NYSE:ABBV [https://seekingalpha.com/symbol/ABBV]) announced that its mid-stage study of Botox (onabotulinumtoxinA) for treating essential tremor in the upper limbs achieved its main goal. The research succ... Full story

Yahoo Finance • 6 days ago

Gilead Sciences settles patent litigations related to Biktarvy

[Intellectual Property] stocknshares Gilead Sciences (NASDAQ:GILD [https://seekingalpha.com/symbol/GILD]) has reached settlement agreements with Lupin, Cipla, and Laurus Labs to resolve patent disputes related to Biktarvy, a medication fo... Full story

Yahoo Finance • 6 days ago

AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

OnabotulinumtoxinA (BOTOX®) met the primary endpoint in the Phase 2 trial, demonstrating a statistically significant improvement from baseline in the Tremor Disability Scale-Revised (TREDS-R) total unilateral score compared to placebo.1 Th... Full story

Yahoo Finance • 6 days ago

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

Over 1,200 participants enrolled in ATMOSPHERE® and ASCENT® pivotal trials, representing largest global gene therapy program ever conducted Subretinal surabgene lomparvovec on track to be first gene therapy for wet AMD Topline pivotal data... Full story

Yahoo Finance • 6 days ago

Eli Lilly will park over $1 billion in India to expand manufacturing footprint

[Indianapolis - April 2016: Eli Lilly and Company V] jetcityimage Pharma giant Eli Lilly (NYSE:LLY [https://seekingalpha.com/symbol/LLY]) is set to invest over $1 billion in India to expand its manufacturing capacity, focusing on contract... Full story

Yahoo Finance • 7 days ago

Notable healthcare headlines for the week: Pfizer, Novo Nordisk and JNJ in focus

Wall Street’s broader market averages closed mixed on Friday as market participants digested the U.S. government shutdown for the third day. For the week, the Dow, S&P 500, and Nasdaq Composite advanced by 1.1%, 1.08%, and 1.32%, respecti... Full story

Yahoo Finance • 8 days ago

Pfizer – TrumpRx deal boosts Big Pharma to a record rally

[President Trump Delivers An Announcement From The Oval Office] Win McNamee/Getty Images News The world’s biggest pharma companies recorded their best weekly performance in years on Friday after Pfizer (NYSE:PFE [https://seekingalpha.com/... Full story

Yahoo Finance • 8 days ago

Notable analyst calls this week: J&J, PayPal and Corteva among top picks

The S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews]) closed in the green on Friday, while Nasdaq (COMP:IND [https://seekingalpha.... Full story

Yahoo Finance • 9 days ago

AbbVie sees negative Q3, full-year impact from IPR&D and milestones expense

[AbbVie] hapabapa * AbbVie (NYSE:ABBV [https://seekingalpha.com/symbol/ABBV#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews]) said it will incur a negative impact of $1.50 to GAAP a... Full story